ESTRO-ISRS 脊柱转移瘤再程立体定向放疗临床实践建议:Delphi 共识及系统综述与荟萃分析
该系统综述与荟萃分析纳入 2006 年 1 月至 2024 年 9 月的 20 项研究(5 项前瞻性、15 项回顾性),共 1284 例患者、1538 处脊柱转移灶接受再程 SBRT。汇总 1 年和 2 年局部控制率分别为 81%(95%CI:77-86%)和 70%(95%CI:61-79%),椎体压缩性骨折、神经根损伤和脊髓病事件汇总比例分别为 5.0%、5.6% 和 1.7%。基于此证据,ESTRO-ISRS 通过 Delphi 共识形成 11 条实践建议,认为再程 SBRT 对经适当选择的脊柱转移患者有效、安全且推荐使用。
要点
- 再程 SBRT 中位剂量为 24 Gy/2 次(范围 16-30 Gy/1-5 次),既往中位常规放疗为 30 Gy/10 次。
- 汇总 1 年局部控制率 81%(95%CI:77-86%),2 年局部控制率 70%(95%CI:61-79%)。
- 椎体压缩性骨折、神经根损伤、脊髓病汇总发生率分别为 5.0%、5.6%、1.7%。
核心结论
- 对于既往接受过常规放疗或 SBRT 的脊柱转移患者,再程 SBRT 有效、安全,是经适当选择患者的推荐治疗选择。
- ESTRO 与 ISRS 联合发布实践建议以指导临床实践,首轮投票即对 11 条建议达成共识。
研究设计与样本
- 系统综述与荟萃分析采用 PRISMA 方法,检索 2006 年 1 月至 2024 年 9 月发表的文献。
- 纳入报告 ≥5 例患者接受脊柱 SBRT 再程照射(每次 ≥5 Gy)治疗椎体转移临床结局的研究。
- 最终纳入 20 项研究(5 项前瞻性、15 项回顾性),共 1284 例患者、1538 处脊柱转移灶。
- 数据作为 ESTRO-ISRS 联合临床实践建议的基础,经 Delphi 共识形成推荐。
主要发现
- 再程照射中位剂量为 24 Gy/2 次(范围 16-30 Gy/1-5 次),既往常规放疗中位剂量为 30 Gy/10 次。
- 椎体压缩性骨折、神经根损伤和脊髓病事件的汇总比例分别为 5.0%、5.6% 和 1.7%。
- 中位随访 12 个月,汇总 1 年局部控制率为 81%(95%CI:77-86%),2 年局部控制率为 70%(95%CI:61-79%)。
- 尽管证据级别低,首轮投票后即对 11 条实践建议达成共识,提示专家间一致性较高。
关键数值与推荐
- 再程 SBRT 推荐用于经适当选择的脊柱转移患者,既往接受过常规放疗或 SBRT。
- 共形成 11 条 ESTRO-ISRS 联合实践建议,首轮 Delphi 投票即达成共识。
临床怎么用
- 对既往接受过脊柱放疗的转移患者,可考虑再程 SBRT 作为挽救治疗。
- 治疗决策应基于患者适当选择,并参考 ESTRO-ISRS 联合实践建议。
- 再程 SBRT 需关注椎体压缩性骨折、神经根损伤和脊髓病等安全性事件。
局限性
- 纳入研究以回顾性为主(15 项回顾性、5 项前瞻性),总体证据级别低。
- 原文指出再程 SBRT 作为挽救治疗的文献有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Stereotactic body radiotherapy (SBRT) is an established treatment for previously unirradiated spinal metastases; however, the literature is limited with respect to SBRT as a re-irradiation salvage therapy. We performed a systematic review and meta-analysis as basis for joint ESTRO-ISRS clinical practice recommendations of salvage SBRT for spinal metastases. METHODS: A systematic review and meta-analysis were performed using PRISMA methodology, including publications from January 2006 to September 2024, reporting on the clinical outcomes of ≥ 5 patients treated with spine SBRT re-irradiation (≥5 Gy per fraction) for vertebral metastases. These data served as basis for joint ESTRO-ISRS clinical practice recommendations. RESULTS: After the initial article screen, 20 studies (5 prospective, 15 retrospective) met the inclusion criteria for analysis. A total of 1538 spine metastases were treated in 1284 patients. The median re-irradiation dose was 24 Gy in 2 fractions (range: 16-30 Gy in 1-5 fractions) after a median 30 Gy in 10 fractions of prior conventional radiotherapy. Vertebral compression fracture, nerve root damage, and myelopathy events were observed in a pooled proportion of 5.0 %, 5.6 %, and 1.7 %, respectively. With a median follow-up of 12 months, the pooled 1- and 2-year LC rates were 81 % (95 % CI: 77-86 %) and 70 % (95 % CI: 61-79 %), respectively. Despite the low level of evidence, a consensus was reached after the first round of voting for 11 practice recommendations, suggesting a substantial level of agreement among the experts. CONCLUSIONS: Re-irradiation with SBRT for spine metastases following prior conventional radiation or SBRT was efficacious, safe, and is a recommended treatment option in appropriately selected patients. Joint practice recommendations are provided on behalf of ESTRO and ISRS to guide clinical practice.
引用
- Alongi F, Cuccia F, Kotecha R, et al. ESTRO-ISRS clinical practice recommendations for re-irradiation of spinal metastases with Stereotactic Body Radiotherapy: Delphi consensus supported by a systematic review and meta-analysis. Radiother Oncol. 2025. PMID: 41344516. doi:10.1016/j.radonc.2025.111304
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。